Showing results (31-40 of 120) with videos related to
Sort By:
Pageof 12
Bladder (San Francisco, Calif.)|August 11, 2020
Outcomes of patients undergoing radiation therapy for bladder cancerSalman Hasan, Eva Mercedes Galvan, Courtney Shaver, et al.Urology|January 17, 2016
Prostate-specific Antigen Mass Density--A Measure Predicting Prostate Cancer Volume and Accounting for Overweight and Obesity-related Prostate-specific Antigen HemodilutionOleksandr N Kryvenko, Mireya Diaz, Andres Matoso, et al.Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|May 15, 2020
The effect of radiation therapy on post-prostatectomy urinary functionDavid K Jenkins, Gregory P Swanson, Sameer G Jhavar, et al.Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|July 18, 2017
Radiobiological evaluation of prostate cancer IMRT and conformal-RT plans using different treatment protocolsPanayiotis Mavroidis, Georgios Komisopoulos, Courtney Buckey, et al.Phytotherapy Research : PTR|September 11, 2014
Tolerance of Phellodendron amurense bark extract (Nexrutine®) in patients with human prostate cancerGregory P Swanson, William E Jones, Chul S Ha, et al.Journal of the American Society of Hypertension : JASH|December 11, 2014
Oscillometric blood pressure: a review for cliniciansBruce S Alpert, David Quinn, David GallickCurrent Urology Reports|May 5, 2005
Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?Edith D Canby-Hagino, Gregory P Swanson, E David Crawford, et al.Brain Injury|May 15, 2003
The mediating effects of effort upon the relationship between head injury severity and cognitive functioningAlan Moss, Christopher Jones, Dene Fokias, et al.Expert Review of Anticancer Therapy|June 18, 2010
Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patientsJoaquim Bellmunt, Mayer Fishman, Timothy Eisen, et al.Critical Reviews in Oncology/Hematology|April 20, 2010
Experience with sorafenib and adverse event managementJoaquim Bellmunt, Timothy Eisen, Mayer Fishman, et al.Pageof 12